期刊
CANCER BIOLOGY & THERAPY
卷 14, 期 12, 页码 1098-1103出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.26343
关键词
colorectal cancer; cetuximab; panitumumab; rechallenge; KRAS
类别
Background: Few data are available outlining outcomes of panitumumab in advanced colorectal cancer patients benefiting from prior cetuximab-based regimens. Patients and methods: Thirty patients with KRaS wild type metastatic colorectal cancer with clinical benefit from prior cetuximab-based regimens between May 2004 and October 2011 were reviewed at nine italian institutions. inclusion key criteria included interruption of cetuximab for reasons other than progressive disease. Patients were classified according to prior regimens (0 or >= 1), prior response or stabilization, surgery of metastases, and Kohne prognostic score. at the time of subsequent progression, patients were treated with single agent panitumumab until progressive disease, unacceptable toxicity, or consent withdrawal. Results: Panitumumab obtained 67% disease control rate and 30% objective response rate, with median PFS of 4.2 and median OS of 9.6 mo. Patients with BRaF/nRaS/Pi3KCa and KRaS (by mutant enriched technique) wild-type tumors had the best chance of response to panitumumab. Conclusions: Single agent panitumumab provided significant clinical benefit in heavily pretreated patients without acquired resistance to prior cetuximab-based regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据